Company: DHR
Filing Date: 2025-07-22
Form Type: 10-Q
Source: 0000313616-25-000153
Chunk: 17

Company: DANAHER CORP /DE/
Filing Date: 2025-07-22
Form: 10-Q
Item: Item 1
Chunk 17
---
 of Product LineDuring the six-month period ended June 27, 2025, the Company divested a product line for a cash purchase price of $9 million and recognized a pretax gain on sale of $9 million ($7 million after-tax).  The divested product line generated revenues of approximately $50 million in the Diagnostics segment in 2024.  The divestiture of this product line did not represent a strategic shift with a major effect on the Company’s operations and financial results and therefore is not reported as a discontinued operation.

NOTE 8.  GOODWILL AND OTHER INTANGIBLE ASSETS 

The following is a rollforward of the Company’s goodwill ($ in millions):Balance, December 31, 2024$40,497 Adjustments due to finalization of purchase price allocations3 Foreign currency translation and other2,491 Balance, June 27, 2025$42,991 The carrying value of goodwill by segment is summarized as follows ($ in millions):June 27, 2025December 31, 2024Biotechnology$23,139 $21,437 Life Sciences12,881 12,305 Diagnostics6,971 6,755 Total$42,991 $40,497 

13

The Company reviews identified intangible assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable.  During the second quarter of 2025, the Company decided to reorganize and integrate certain businesses within its Life Sciences segment to better serve the Company’s customers in new market segments and to respond to current market conditions.  As a result of these plans, the Company concluded that an indefinite-lived trade name within the genomics consumables business was no longer considered to be indefinite-lived, resulting in an impairment indicator.  The Company engaged a third-party valuation specialist to assist in the valuation of the trade name using a relief from royalty method of valuation.  The significant assumptions in the relief from royalty method include, but were not limited to, revenue, revenue growth rates, planned use of the trade name, royalty rates and discount rates.  The Company recorded a noncash impairment charge of $432 million pretax ($328 million after-tax) related to the trade name for the three and six-months ended June 27, 2025, which is included in selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings.  The amount of the impairment